A. Richters

发表

Proteus in the World of Proteins: Conformational Changes in Protein Kinases

Daniel Rauh, D. Rauh, Matthäus Getlik, 2010, Archiv der Pharmazie.

Neuritogenic militarinone-inspired 4-hydroxypyridones target the stress pathway kinase MAP4K4.

Herbert Waldmann, Daniel Rauh, Slava Ziegler, 2015, Angewandte Chemie.

Identification of cancer driver genes based on nucleotide context

E. Lander, S. Sunyaev, E. V. Van Allen, 2019, Nature Genetics.

Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34.

H. Waldmann, H. Osada, D. Rauh, 2017, Angewandte Chemie.

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

Roman K. Thomas, G. Kéri, M. Peifer, 2017, Cell reports.

Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease.

A. Koehler, A. Richters, 2017, Current medicinal chemistry.

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

Roman K. Thomas, T. Zander, M. Peifer, 2014, Cancer discovery.

Discovery of cancer driver genes based on nucleotide context

E. Lander, S. Sunyaev, E. V. Van Allen, 2018 .

Identification and further development of potent TBK1 inhibitors.

Roman K. Thomas, D. Rauh, H. Balke-Want, 2015, ACS chemical biology.

Targeting protein arginine methyltransferase 5 in disease.

A. Richters, 2017, Future medicinal chemistry.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

A. Trumpp, A. Bradley, R. Rad, 2015, Cell.

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Herbert Waldmann, Takashi Ninomiya, Martin Peifer, 2012, Proceedings of the National Academy of Sciences.

Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.

M. Radi, C. Tintori, F. Musumeci, 2015, Journal of medicinal chemistry.

Identification of cancer driver genes based on nucleotide context

E. Lander, S. Sunyaev, E. V. Van Allen, 2020, Nature Genetics.

Kovalent‐allosterische Kinase‐Inhibitoren

P. Janning, S. Pelly, Zhizhou Fang, 2015 .

Covalent-Allosteric Kinase Inhibitors.

P. Janning, S. Pelly, W. V. van Otterlo, 2015, Angewandte Chemie.

Identification of type II and III DDR2 inhibitors.

H. Nguyen, T. Phan, C. Grütter, 2014, Journal of medicinal chemistry.

De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments

Daniel Rauh, Brad Sherborne, Michael Kiczun, 2013, ACS chemical biology.

A chemical genetic approach for covalent inhibition of analogue-sensitive aurora kinase.

André Koch, D. Rauh, A. Richters, 2012, ACS chemical biology.

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.

D. Rauh, A. Richters, Debjit Basu, 2015, Bioorganic & medicinal chemistry.

Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer

K. Shokat, Roman K. Thomas, M. Peifer, 2017 .

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

K. Shokat, Roman K. Thomas, M. Peifer, 2017, Science Translational Medicine.

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.

Roman K. Thomas, M. Sos, Anu Gupta, 2013, Journal of medicinal chemistry.

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.

Jochen Heil, Franziska Hoffgaard, Julian Engel, 2015, Journal of medicinal chemistry.

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

Charles Y. Lin, S. Knapp, T. Westbrook, 2020, Cell chemical biology.

An Array-Based Ligand Discovery Platform for Proteins With Short Half-Lives.

A. Koehler, A. Richters, Shelby K. Doyle, 2018, Methods in enzymology.

Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.

M. E. Beck, P. Schreier, J. Pérez-Martín, 2012, ACS chemical biology.

Metabolically stable dibenzo[b,e]oxepin-11(6H)-ones as highly selective p38 MAP kinase inhibitors: optimizing anti-cytokine activity in human whole blood.

S. Laufer, M. Goettert, D. Rauh, 2013, Journal of medicinal chemistry.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

A. Trumpp, A. Bradley, R. Rad, 2015, Cell.

A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.

M. Radi, C. Tintori, A. L. Fallacara, 2016, Bioorganic & medicinal chemistry letters.